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The human and bovine forms of the hydrophobic 3.7 kDa surfactant polypeptide have been structurally analyzed. The 
polypeptide is essentially inert to enzymatic proteolysis, and methods for analysis include peptide handling in organic 
solvents and fragment generation by limited acid hydrolysis. The molecule xhibits N-terminal trimming, and the relative 
abundance of the different starting positions varies both among species and between adult and fetal forms of the surfac- 
tant polypeptide. The bovine major form is one residue shorter than the mature 35-residue human molecule. Comparison 
of the porcine, human and bovine polypeptides reveals a conserved hydrophobic middle/C-terminal segment and a vari- 
able hydrophilic N-terminal part. 
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1. INTRODUCTION 
Pulmonary surfactant is essential for normal 
lung function by reducing the surface tension at 
the air/liquid interface [l]. Its major components 
are phospholipids, especially 1,2-dipalmitoyl-sn- 
glycero-3-phosphocholine, hydrophilic proteins 
(28-36 kDa) and hydrophobic proteins (3-18 
kDa) [2]. Replacement herapy with different sur- 
factant preparations in preterm neonates has 
shown that the phospholipids and the hydrophobic 
proteins are the essential components of exogenous 
surfactants [3-71. In previous studies, we have 
isolated and characterized the two major types of 
hydrophobic low-molecular-mass protein from 
porcine lung [8-lo]. Both proteins exhibit some N- 
terminal heterogeneity, with forms starting at dif- 
ferent positions; the two polypeptides consist in 
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their longest forms of 79 and 35 residues, respec- 
tively [9, lo], corresponding to molecular masses of 
8.7 and 3.7 kDa. Recombination of either of these 
polypeptides with synthetic phospholipids yields 
preparations that are surface-active both in vitro 
and in experiments on premature newborn rabbits 
B39101. 
The 35residue polypeptide, which is the major 
hydrophobic protein in pulmonary surfactant, has 
unusual solubility properties, is resistant to en- 
zymatic cleavage, and is to some extent inert even 
to chemical degradation [lo]. N-terminal amino 
acid sequence analysis of the human [l l] and 
bovine [12-141 forms of this polypeptide and the 
nucleotide sequence of a corresponding human 
cDNA structure [ 151 have recently been reported 
but, except for the structure of the porcine form 
[lo], information on the size, C-terminal end, or 
all amino acid replacements has not been given. In 
the present study, we characterize the structure, in- 
cluding the C-terminal end, of the major human 
and bovine forms of the hydrophobic surfactant 
polypeptide. 
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Table 1 
Relative occurrence of the differently truncated forms found in 
adult and fetal human hydrophobic 3.7 kDa surfactant 
polypeptide 
N-terminal structure Occurrence (vo) 
Adult Fetal 
F G” I P C C - 60 30 
calpcc-+ 20 40 
IPCC- 20 30 
a Arg detected (lo-25%) together with Gly at position 2 
2. MATERIALS AND METHODS 
2. I. Protein preparations 
Bronchoalveolar lavage fluid was obtained from healthy 
adults by instillation of sterile saline (5 x 50 ml), and subse- 
quent gentle aspiration (approved by ethical committee). The 
fluid was filtered and centrifuged, 400 x g at 4°C for 5 min 
[16]. Amniotic fluid was obtained from full-term pregnancies 
and was filtered before protein isolation. 
Portions of 300 ml amniotic fluid or bronchoalveolar lavage 
fluid were mixed with 400 ml methanol. After addition of 
800 ml chloroform, the lower phase was filtered and evaporated 
to dryness. The extract was separated by reverse-phase 
chromatography on Lipidex-5000 in a system of ethylene 
chloride/methanol, 1: 4 (by vol.). The hydrophobic proteins in 
the phospholipid fraction were separated into two fractions by 
Sephadex LH-60 chromatography [8] and the protein in the se- 
cond fraction was submitted to sequence analysis. The cor- 
responding protein from bovine and human lung tissue was 
isolated as described [8-lo]. 
2.2. Structural analysis 
The pure polypeptides were reduced, [‘4C]carboxymethylated 
and separated from excess reagents [8,9]. Limited acid 
1 
hydrolysis was performed with 12 M HCl for 24 h at ambient 
temperature. The hydrophilic and hydrophobic fragments pro- 
duced were separated using a chloroform/methanol/water 
(8 : 4: 3, by vol.) system [lo]. Hydrophilic peptides recovered in 
the methanol/water phase were separated by HPLC on an 
Ultropac TSK Cl8 column with a linear gradient of acetonitrile 
in 0.1% trifluoroacetic acid. Peptides were subjected to se- 
quence analysis in an Applied Biosystems 470A gas-phase in- 
strument and a Beckman 89OD liquid-phase instrument. 
Phenylthiohydantoin derivatives were detected by HPLC using 
a Hewlett-Packard 1090 instrument or an Applied Biosystems 
120A on-line system. 
Amino acid compositions were obtained after hydrolysis in 
evacuated tubes with 6 M HCl/0.5% phenol for 24 h at 110°C 
and for 72 h at 150°C [lo]. Hydrazinolysis was performed with 
anhydrous hydrazine for 6 h at 110°C. Amino acids were deter- 
mined with a Beckman 121M instrument. 
3. RESULTS 
3.1. Human polypeptides 
Direct degradations of intact material of adult 
(bronchoalveolar lavage fluid) and fetal (amniotic 
fluid) origin gave identical results upon analysis of 
the N-terminal 30 residues. However, both the 
adult and the fetal polypeptide showed a complex 
pattern of N-terminal heterogeneity, with peptide 
chains starting at positions 1, 2 and 3 (all numbers 
according to the longest form; table 1). At position 
2, results suggest he occurrence of both Gly and 
Arg. The further analysis to establish the complete 
structure of the human low-molecular-mass ur- 
factant protein was performed with the material 
from the amniotic fluid. 
The peptides isolated from the lipophilic phase 
10 20 
Phe-Gly/Arg-Ile-Pro-Cys-Cys-Pro-Val-His-~eu-Lys-Arg-Leu-Leu-Ile-Val-Val-Val-Val-Val- 
Intact 
Hl -H4- Ll 
H2 -H3- 
30 35 
-Val-Leu-Ile-Val-Val-Val-Ile-Val-Gly-Ala-Leu-Leu-Met-Gly-Leu 
I”taot- _ - - - ____ - - 
Ll 
Fig. 1. Amino acid sequence of human hydrophobic 3.7 kDa surfactant polypeptide and fragments analyzed. Only the mature, full- 
length sequence is shown, but truncated forms starting at positions 2 and 3 were found (cf. section 3). At position 2, both Gly and 
Arg occur. Intact, results from degradations of uncleaved material. Hl-H7 and Ll, peptides generated by limited acid hydrolysis and 
separated into a hydrophilic (Hl-H7) and lipophilic (Ll) phase. Continuous lines, peptide regions determined by sequence analysis; 
dashed line, region supported by total composition. 
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Fig.2. Elution profile of peptides produced by limited acid 
hydrolysis and recovered in the water/methanol phase of the 
chloroform/methanol/water system. Peptide designations as in 
fig. 1. The peptides were separated by high-performance liquid 
chromatography on an Ultropac TSK Cl8 column (flow 
1 ml/min) with a linear gradient of acetonitrile in 0.1% 
trifluoroacetic acid. 
of the chloroform/methanol/water system after 
limited acid hydrolysis of the intact polypeptide 
consisted of fragments from the extremely 
hydrophobic middle third of the molecule, mixed 
with uncleaved material. Direct degradation of the 
fragments in the mixture established the sequence 
for positions 14-30 (fig.1). The peptides in the 
methanol/water phase were purified by HPLC 
(fig.2). Sequence analysis of these peptides 
established the structure of the N- and C-terminal 
fragments (fig.1). The C-terminal end was also 
confirmed by recovery of free leucine after 
hydrazinolysis of intact material, both from lung 
tissue and amniotic fluid. Thus, the human 
hydrophobic 3.7 kDa surfactant polypeptide has 
35 residues in its longest form and the amino acid 
sequence is given in fig.i. These results are in 
agreement with the total composition from acid 
hydrolysis, provided extensive hydrolysis is carried 
out to liberate all residues [lo] of this extremely 
hydrophobic polypeptide. 
Human F G/R 
Porcine 
Bovine 
L R 
L 
-I rl 0 IPCCPVHLKRLL 
3.2. Bovine polypeptide 
Degradation of the intact material established 
positions l-33 (fig.3). Sequence analysis of two 
hydrophilic peptides, generated by limited acid 
hydrolysis and separated by HPLC as for the 
human polypeptide, gave the N- and C-terminal 
regions (positions l-10 and 29-34). Free leucine 
was recovered upon hydrazinolysis of intact pro- 
tein. This defines the structure of the 3.7 kDa 
bovine hydrophobic surfactant polypeptide as a 
34-residue molecule (fig.3). This structure is also in 
agreement with results from amino acid analysis 
after extensive acid hydrolysis. The bovine 
polypeptide exhibits N-terminal trimming with 
starts at either of the first two positions, with a 
relative occurrence of 85 and 15% (long and short 
form, respectively). 
4. DISCUSSION 
4.1. Sequence analysis and N-terminal 
heterogeneities 
The direct analyses of the intact material were 
complicated by multiple starting points and the ex- 
tremely hydrophobic middle third of the molecule. 
The fetal and adult human polypeptides (as well as 
the porcine polypeptide [8,10]) have starting points 
at positions l-3, whereas the native, mature 
bovine polypeptide has only two starting points, 
and lacks a residue corresponding to position 1 
(fig.3; or to position 2, wher the gap alternatively 
could be positioned) in the other forms. The 
relative abundance of the different forms varies 
both among the three species and between the 
adult and fetal human polypeptides (table 1). 
Regarding the human polypeptide, evidence sug- 
gests a polymorphism at position 2 (fig.1). 
Although peptides with either Gly or Arg at this 
position could not be purified after limited acid 
hydrolysis, the recoveries of these residues are con- 
I 
30 
IVVVIVGALLMGL 
VVVVIVGALLHGL 
LVVVIVGALLMGL 
Fig.3. Comparison of the structures of human, porcine and bovine 3.7 kDa hydrophobic surfactant polypeptide. Residue exchanges 
are boxed. 
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sidered likely to represent a polymorphism since all 
degradations of intact material and N-terminal 
peptides (fig. 1) yielded both these residues at posi- 
tion 2. Their relative abundance is similar in the 
adult and fetal polypeptide (table 1); in both cases 
forms with Arg appear to be slightly more com- 
mon (25% versus 10%) in the full-length molecules 
starting at Phe than in the truncated forms. 
The total compositions of both the human and 
bovine polypeptides can only be correctly obtained 
after non-conventional, extensive acid hydrolysis 
as for the porcine protein [IO]. After hydrolysis for 
3 days at 15O”C, liberated hydrophobic residues 
are in excellent agreement with the results from the 
sequence analysis. 
4.2. Structural comparison of the human, porcine 
and bovine hydrophobic 3.7 kDa surfactant 
polypeptides 
With the present report, it is possible to compare 
the 3.7 kDa polypeptides of human, porcine, and 
bovine origin. Previous reports on the structures of 
the human and bovine polypeptides, deduced from 
analyses at the protein level have been incomplete 
[ 1 l- 141, and a human cDNA sequence did not 
establish the exact size of the mature, native, and 
biologically active molecule [ 151. However, the 
major form of the human polypeptide now de- 
fined, with Gly at position 2, is identical to a seg- 
ment of the structure deduced from the cDNA 
reported. 
Alignment of the human, porcine and bovine 
polypeptides reveals identical residues at 83% of 
all positions (fig.3). The first two residues (in the 
numbering system of the human and porcine 
forms) show no consistent pattern between the 
three species and at position 9 an exchange affec- 
ting the net charge is found. The hydrophobic 
region starting at position 13 is conserved in 
properties, revealing only single branched-chain 
residue exchanges, and exhibiting identical 
12-residue C-terminal segments in all three 
polypeptides. Interestingly, the residue at position 
23 is different among the polypeptides, but is in all 
cases an aliphatic, branched-chain residue. Thus, 
the 3.7 kDa surfactant polypeptide has a general 
structure of two distinct parts [lo], one hydrophilic 
N-terminal segment and one extremely hydropho- 
bic, middle/C-terminal part, as expected for a 
structure with surfactant properties. The more 
64 
variable N-terminal part, with size differences, 
residue exchanges, multiple starting points, and 
possibly residue polymorphism, suggests less con- 
straints on the N-terminal segment and emphasizes 
the importance of the middle/C-terminal, 
hydrophobic part for the function of the surfac- 
tant polypeptide. 
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